Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
SHR-1501 in Advanced Malignancies
NCT04025957Phase 1Completed
- Sponsor
- Hengrui
- Start
- Oct 2019
- Primary completion
- Jul 2022
- Modality
- Antibody-Drug Conjugates (ADCs), Monoclonal Antibodies, Fc-Fusion Proteins
- Countries
- 1
01
Overview
Phase 1, open-label trial of SHR-1501 in malignant neoplasms (advanced stage), sponsored by Hengrui. Primary endpoints: Dose-limiting toxicity at 2 years, Maximum tolerated dose at 2 years and 1 more. Started Oct 2019; status: completed.
02
Drugs
SHR-1501
03
Conditions
malignant neoplasms (advanced stage)
Beyond the preview
Go deeper on NCT04025957.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04025957.